BSD Medical Hyperthermia Systems Featured at European Society for Hyperthermic Oncology Annual Conference

  BSD Medical Hyperthermia Systems Featured at European Society for
  Hyperthermic Oncology Annual Conference

Business Wire

SALT LAKE CITY -- July 9, 2014

BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD) (, a
leading provider of medical systems that utilize heat therapy to treat cancer,
today announced BSD hyperthermia systems were featured in multiple
presentations at the European Society for Hyperthermic Oncology (ESHO) Annual
Conference. There were many presentations during the conference regarding
innovative uses of thermal therapy in the treatment of patients with a variety
of cancers. The results of two innovative clinical studies using BSD's
hyperthermia systems were presented during the conference.

Dall’Oglio et al., presented data from a study of 144 patients with high risk
prostate cancer who were treated using the BSD-2000 Hyperthermia System
(BSD-2000) at the University Hospital in Verona, Italy. The presentation was
titled "Regional hyperthermia added to hormonal therapy and radiotherapy in
T2b -T4 prostate cancer - long-term follow up results." The patients received
hyperthermia combined with hormonal therapy and external beam radiotherapy.
After a median follow-up of 75.7 months, overall survival was 87% and
disease-free survival was 49%.

Puric et al., Aarau, Switzerland, reported results from a retrospective study
of the safety and efficacy of hyperthermia, delivered using the BSD-500
Hyperthermia System, combined with radiation in the management of patients
with recurrent breast cancer who had received previous radiation. The study,
"Hyperthermia and re-irradiation for postirradiated locoregionally recurrent
breast cancer: a single institutional experience," involved 24 previously
irradiated patients. The researchers reported a complete response rate of
66.7% (16/24) and an overall objective response rate (complete plus partial
response) of 91.7% (22 of 24 patients). The follow-up ranged from 1 to 38
months with a median follow-up of 10 months. The researchers concluded that,
"Local thermoradiotherapy is an effective and safe modality to treat
loco-regional recurrences in previously irradiated breast cancers. It produces
sustainable long term effective palliation with minimal morbidity."

About the BSD-2000 Hyperthermia System

The BSD-2000 – developed and patented exclusively by BSD – delivers localized
therapeutic heating (hyperthermia) by applying radiofrequency (RF) energy. The
BSD-2000 creates a central focusing of energy that can be electronically
focused to target the shape, size and location of the tumor, thus providing
dynamic control of the heating delivered to the tumor region. The BSD-2000 has
Humanitarian Device Exemption (HDE) marketing approval from the U.S. Food and
Drug Administration (FDA) for use in conjunction with radiation therapy for
the treatment of cervical cancer patients who are ineligible for chemotherapy.
The BSD-2000 also has CE (Conformité Européenne) Marking approval for the
commercial sale in Europe. CE Marking approval is also recognized in many
countries outside of the EU.

About the BSD-500 Hyperthermia System

The BSD-500 Hyperthermia System is used to deliver therapeutic heating
(hyperthermia) using either non-invasive (external) hyperthermia, which is
delivered using antennas placed over the tumor, or interstitial hyperthermia,
which is delivered using antennas that are inserted into the tumor, or a
combination of both. The BSD-500 has received U.S. Food and Drug
Administration (FDA) pre-market approval (PMA) for the use of hyperthermia in
conjunction with radiation therapy to treat certain tumors.

About BSD Medical Corporation

BSD Medical Corporation develops, manufactures, markets and services systems
to treat cancer and benign diseases using heat therapy, which is delivered
using focused radiofrequency (RF) and microwave energy. BSD’s product lines
include both hyperthermia and ablation treatment systems. BSD’s hyperthermia
cancer treatment systems, which have been in use for several years in the
United States, Europe and Asia, are used to treat certain tumors with heat
(hyperthermia) while increasing the effectiveness of other therapies such as
radiation therapy. BSD’s microwave ablation system has been developed as a
stand-alone therapy to employ precision-guided microwave energy to ablate
(destroy) soft tissue. The Company has developed extensive intellectual
property, multiple products in the market and established distribution in the
United States, Europe and Asia. Certain of the Company’s products have
received regulatory approvals and clearances in the United States, Europe and
China. For further information visit BSD Medical's website at

This press release may be deemed to contain forward-looking statements, which
are subject to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Readers are cautioned that these forward-looking
statements are only predictions and may differ materially from actual future
events or results due to a variety of factors, including, among other things,
the demand for the Company’s products, the ability of the Company to produce
the products to meet the demand, global economic conditions and uncertainties
in the geopolitical environment and other risk factors set forth in the
Company’s most recent reports on Form 10-K and Form 10-Q. Any forward-looking
statements in this release are based on limited information currently
available to the Company, which is subject to change, and the Company will not
necessarily update the information.


Financial Profiles
Tricia Ross, 310-622-8226
Press spacebar to pause and continue. Press esc to stop.